IntelGenx Technologies shareholder conference call to update shareholders on CPI-300

Horst G. Zerbe, President and CEO of IntelGenx Technologies Corp. ("IntelGenx") will be holding a shareholder conference call to update shareholders on the company's CPI-300 product and remark on related legal proceedings. The call will be held on Tuesday September 1, 2009 at 2.30 p.m. Eastern Standard Time.

Conference Call

Date: Tuesday, September 1, 2009
Time: 2:30 p.m. Eastern Standard Time
Local Dial-In Number: 719-457-2629
Toll Free North America: 888-300-2343
Passcode: 4094736


To participate in the call, please dial 888-300-2343 or 719-457-2629 five to ten minutes prior to the 2.30 p.m. start of the teleconference. The passcode for the call will be 4094736. This conference call will be recorded and archived for 30 days, and can be accessed beginning on the business day following the conference call by visiting IntelGenx's website, at www.intelgenx.com, and clicking on the "Investors" link. A transcript of the call will also be made available on IntelGenx's website at www.intelgenx.com and can be viewed at www.sec.gov under cover of Form 8-K filed on September 1, 2009.

CPI-300:

CPI-300 was formulated using IntelGenx's proprietary controlled release technology. It contains a new strength of a widely prescribed antidepressant. CPI-300 was developed to broaden the dosing options for physicians while providing a more convenient dosing option for patients requiring a higher strength of the products currently available. It will be indicated for the treatment of major depressive disorder.

http://www.intelgenx.com/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.